Cancer Research Technology (CRT)

£50m CRT Pioneer Fund announces investment to develop lung cancer drugs at Cancer Research UK’s Manchester Institute

The CRT Pioneer Fund announces a collaboration with the Cancer Research UK Manchester Institute Drug Discovery Unit. The CRT Pioneer Fund announces a collaboration with the Cancer Research UK Manchester Institute Drug Discovery Unit.

21 November 2014

Cancer Research UK and Medimmune establish joint CRUK-Medi alliance laboratory to develop new biologic cancer medicines

Cancer Research Technology (CRT) has announced a collaboration with AstraZeneca and MedImmune to establish a joint laboratory in Cambridge. Cancer Research Technology (CRT) has announced a collaboration with AstraZeneca and MedImmune to establish a joint laboratory in Cambridge.

25 September 2014

• Health & Medicine

Cancer Research UK and Cancer Research Technology join forces with Astellas on autophagy to find new cancer treatments

Cancer Research UK and its commercial arm, Cancer Research Technology are to join forces with Astellas Pharma Inc. Cancer Research UK and its commercial arm, Cancer Research Technology are to join forces with Astellas Pharma Inc.

8 August 2014

Cancer Research UK’s Drug Development Office and Astex join forces to trial potential new cancer treatments

Cancer Research UK has announced that Astex Pharmaceuticals will join its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance Cancer Research UK has announced that Astex Pharmaceuticals will join its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance

14 May 2014

• Health & Medicine

Promising results in phase 1 trial lead immatics to continue work on vaccine (IMA950) for glioblastoma

A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a Cancer Research UK trial. A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a Cancer Research UK trial.

23 April 2014

• Health & Medicine

CRT and Teva’s collaboration yields successful outcome with novel aPKC protein inhibitor cancer drug development candidate

CRT announces a successful outcome to collaborating with Teva - identiying a novel atypical Protein Kinase C (aPKC) inhibitor pre-clinical candidate. CRT announces a successful outcome to collaborating with Teva - identiying a novel atypical Protein Kinase C (aPKC) inhibitor pre-clinical candidate.

7 April 2014

• Health & Medicine

Cancer Research UK drug launched in its first clinical trial

A new cancer drug, RG7813, developed after a discovery made by Cancer Research UK, has entered a clinical trial targeting a wide range of cancers. A new cancer drug, RG7813, developed after a discovery made by Cancer Research UK, has entered a clinical trial targeting a wide range of cancers.

27 March 2014

• Science & Technology

International deal to screen potential cancer drugs using DNA 'barcodes'

A screening technology tags compounds with strands of DNA to assess prototype drugs for anti-cancer activity. A screening technology tags compounds with strands of DNA to assess prototype drugs for anti-cancer activity.

22 January 2014

• Health & Medicine

Cancer Research UK and AstraZeneca sign deal to repurpose asthma drug that could fight kidney cancer

Cancer Research UK and Cancer Research Technology have reached an agreement with AstraZeneca to take AZD2098, into a kidney cancer clinical trial. Cancer Research UK and Cancer Research Technology have reached an agreement with AstraZeneca to take AZD2098, into a kidney cancer clinical trial.

23 December 2013

CRT, University of Manchester and Glaxosmithkline work together to generate new cancer drugs

Cancer Research Technology and the University of Manchester today announced a research agreement with GlaxoSmithKline to generate new cancer drugs. Cancer Research Technology and the University of Manchester today announced a research agreement with GlaxoSmithKline to generate new cancer drugs.

29 November 2013

CRT Pioneer Fund collaborates with Chroma Therapeutics to develop cancer drugs targeting the immune system

The Cancer Research Technology Pioneer Fund has announced a collaboration with Chroma Therapeutics Ltd to develop drugs targeting macrophages. The Cancer Research Technology Pioneer Fund has announced a collaboration with Chroma Therapeutics Ltd to develop drugs targeting macrophages.

31 October 2013

CRT Pioneer fund, BACIT and SAREUM enter agreement to fund development of drugs to treat cancers including pancreatic, bowel and lung

The funding will enable the project to move swiftly towards, and potentially into Phase I clinical trials. The funding will enable the project to move swiftly towards, and potentially into Phase I clinical trials.

24 September 2013